Hepatobiliary adverse-event reporting patterns for endocrine therapies in breast cancer: a pharmacovigilance study based on FAERS and VigiAccess.

Mao W, Liu Y, Liu B, Zhu B

Open source

DOI
10.3389/fendo.2026.1940744
Published
2026
Container
Frontiers in endocrinology
Publisher
Not recorded
Open access
yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.3389/fendo.2026.1940744,
  title = {Hepatobiliary adverse-event reporting patterns for endocrine therapies in breast cancer: a pharmacovigilance study based on FAERS and VigiAccess.},
  author = {Mao W and Liu Y and Liu B and Zhu B},
  year = {2026},
  journal = {Frontiers in endocrinology},
  doi = {10.3389/fendo.2026.1940744},
  url = {https://doi.org/10.3389/fendo.2026.1940744}
}

RIS

TY  - JOUR
TI  - Hepatobiliary adverse-event reporting patterns for endocrine therapies in breast cancer: a pharmacovigilance study based on FAERS and VigiAccess.
AU  - Mao W
AU  - Liu Y
AU  - Liu B
AU  - Zhu B
PY  - 2026
JO  - Frontiers in endocrinology
DO  - 10.3389/fendo.2026.1940744
UR  - https://doi.org/10.3389/fendo.2026.1940744
ER  - 

APA

W, M., Y, L., B, L., & B, Z. (2026). Hepatobiliary adverse-event reporting patterns for endocrine therapies in breast cancer: a pharmacovigilance study based on FAERS and VigiAccess.. Frontiers in endocrinology. https://doi.org/10.3389/fendo.2026.1940744

Source records